

Appendix 1: Excluded studies on full text

Study	Year	Journal	Reason for exclusion
<p>Gundogdu M, Kundakci N, Erdem C. Assessment of Life Quality Index and Treatment Efficacy in Psoriasis Vulgaris Patients Receiving Biologic Therapies in a Turkish Population. <i>Skinmed.</i> 2020;18(2):84-90.</p>	<p>2020</p>	<p>Skinmed</p>	<p>Full text unavailable</p>
<p>Jensen JD, Delcambre MR, Nguyen G, Sami N. Biologic therapy with or without topical treatment in psoriasis: what does the current evidence say? <i>Am J Clin Dermatol.</i> 2014;15(5):379-385.</p>	<p>2014</p>	<p>American Journal of Clinical Dermatology</p>	<p>No measurement of quality of life when using biologics</p>
<p>Carretero G, Puig L, Carrascosa JM, et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. <i>J Dermatolog Treat.</i> 2018;29(4):334-346.</p>	<p>2018</p>	<p>Journal of Dermatological Treatment</p>	<p>No measurement of quality of life when using biologics</p>
<p>Navarini AA, French LE. Survival of Second-Line Biologics in Psoriasis: The British BADBIR Registry Data</p>	<p>2018</p>	<p>Journal of Investigative Dermatology</p>	<p>No measurement of quality of life when using biologics</p>

<p>Informs Daily Practice. <i>J Invest Dermatol.</i> 2018;138(4):726-728.</p>			
<p>Alten R, Conaghan PG, Strand V, et al. Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study. <i>Clin Rheumatol.</i> 2019;38(6):1615-1626.</p>	<p>2019</p>	<p>Clin Rheumatology</p>	<p>No measurement of quality of life when using biologics</p>
<p>Ellis AG, Flohr C, Drucker AM. Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN, Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. <i>J Invest Dermatol</i> 2017; 137:1646-54. Sbidian E, Chaimani A, Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>Cochrane Database Syst Rev</i> 2017; 12:CD011535. <i>Br J Dermatol.</i> 2019;180(2):282-288.</p>	<p>2019</p>	<p>British Journal of Dermatology</p>	<p>No measurement of quality of life when using biologics</p>

<p>Wang Q, Li M, Hu X, Luo Q, Hao P. Autologous blood or autologous serum acupoint injection therapy for psoriasis vulgaris: A protocol for a systematic review and meta-analysis. <i>Medicine (Baltimore)</i>. 2020;99(23):e20555.</p>	<p>2020</p>	<p>Medicine (Baltimore)</p>	<p>No measurement of quality of life when using biologics</p>
<p>Kojanova M, Fialova J, Cetkovska P, et al. Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic. <i>Dermatol Ther</i>. 2021;34(2):e14849.</p>	<p>2021</p>	<p>Dermatologic Therapy</p>	<p>No measurement of quality of life when using biologics</p>